Type 2 diabetes mellitus (T2DM) is a constantly progressing disease and monotherapy may last for approximately 5–10 years before a further increase in glycated hemoglobin (HbA1c) indicates the requirement of a combination therapy. We conducted a review focusing our attention on the effects of a combination of rosiglitazone plus glimepiride on metabolic control. We performed a defined search str...

Background and Objectives: Peroxisome proliferator-activated receptor- (PPAR-) is a nuclear receptor whose activation regulates inflammation and fibrosis in various organs. We aimed to investigate the effect of two PPAR- ligands, telmisartan and rosiglitazone, on lung injury and fibrosis induced by intratracheal bleomycin (BLM). Methods: Lung injury and fibrosis was induced in female C57Bl/6...

Diabetes mellitus is associated with a number of prothrombotic abnormalities, and correction of these abnormalities might translate into the reduction of cardiovascular risk. Glitazones improve endothelial function and reduce inflammation, but much less is known about their effect on thrombogenic factors. We have therefore studied the effect of rosiglitazone on leukocyte and soluble thrombogeni...

PURPOSE Exercise training with PPARγ agonist is expected to increase glucose uptake and improve insulin sensitivity in skeletal muscle of patients with diabetes. However, its mechanisms to effect glucose uptake and insulin sensitivity in skeletal muscle are unclear. METHODS The mechanism of action was determined by co-treatment with PPARγ agonist- rosiglitazone and exercise training in strept...

Delivering medicine to the general circulation through the skin is associated with grater advantages compared to that by the oral route and hence the purpose of this investigation was to study the potential of rosiglitazone maleate for transdermal delivery using passive diffusion and iontophoresis. Physicochemical parameters of rosiglitazone maleate like solubility, pKa, octanol/vehicle and ski...

Benkirane, Karim, Farhad Amiri, Quy N. Diep, Mohammed El Mabrouk, and Ernesto L. Schiffrin. PPARinhibits ANG IIinduced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290: H390–H397, 2006. First published September 9, 2005; doi:10.1152/ajpheart.00662.2005.—The present study evaluated the effects of peroxisome proliferator-activated receptor (PPAR)activators on ANG II-induced s...

PPARgamma ligands inhibit the proliferation of non-small cell lung carcinoma (NSCLC) cells in vitro. The mechanisms responsible for this effect remain incompletely elucidated, but PPARgamma ligands appear to inhibit the mammalian target of rapamycin (mTOR) pathway. We set out to test the hypothesis that PPARgamma ligands activate tuberous sclerosis complex-2 (TSC2), a tumor suppressor gene that...

AIMS Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. METHODS A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular rel...

OBJECTIVE The purpose of this study was to examine the effects of PPAR-gamma agonist rosiglitazone, relative to sulfonylureas, on circulating levels of adiponectin and the prothrombotic factor, plasminogen activator inhibitor (PAI)-1, in type 2 diabetic patients, and to investigate, in animal models, whether the antithrombotic action of rosiglitazone was mediated through adiponectin. METHODS ...

Pulmonary arterial hypertension (PAH) is a fatal disease characterized by a progressive increase in pulmonary arterial pressure leading to right ventricular failure and death. Activation of the endothelin (ET)-1 system has been demonstrated in plasma and lung tissue of PAH patients as well as in animal models of PAH. Recently, peroxisome proliferator-activated receptor γ (PPAR γ ) agonists have...